The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LXRX | +56.63% | -66.03% | -19.42% | -99% |
| S&P | +11.09% | +81.2% | +12.62% | +343% |
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Express Scripts will give its clients access to Lexicon's first approved therapy.
Lexicon Pharmaceuticals' fundraising activity is painful for shareholders right now, but it's critical.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $14.18M | 710.4% |
| Gross Profit | $14.02M | 802.8% |
| Gross Margin | 98.86% | 10.1% |
| Market Cap | $490.59M | -13.6% |
| Market Cap / Employee | $4.76M | 0.0% |
| Employees | 103 | -63.9% |
| Net Income | -$12.77M | 80.3% |
| EBITDA | -$12.04M | 81.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $49.66M | 43.7% |
| Accounts Receivable | $2.33M | -19.4% |
| Inventory | 0.2 | -75.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $63.30M | -39.5% |
| Short Term Debt | $1.64M | 26.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.02% | 45.9% |
| Return On Invested Capital | -68.55% | -23.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$23.83M | 55.8% |
| Operating Free Cash Flow | -$23.83M | 55.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.50 | 1.14 | 2.79 | 3.79 | 19.21% |
| Price to Sales | 8.59 | 5.35 | 5.88 | 6.92 | -93.62% |
| Price to Tangible Book Value | 1.99 | 1.64 | 4.38 | 5.78 | 36.40% |
| Enterprise Value to EBITDA | -5.70 | -3.07 | 68.07 | -36.52 | 459.36% |
| Return on Equity | -167.7% | -86.1% | -65.3% | -45.9% | -66.02% |
| Total Debt | $106.07M | $106.26M | $61.45M | $64.95M | -38.66% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
